Dex??s Laboratory:
a funny freebie.

VID-19 patients, the vaccine should build a

l. Compared w
Collect from ???/




adenovirus a


s the vector, the va


ccine carries the gene of the coronavirus spike protein, the major surface protein used by the virus to bind to a

receptor to invade cells, so that the subject's body will produce the immunological memory of the protein. When the real coronavirus attacks, the body will identify its spike protein and stop its invasion, according to Chen. The 108

e first phase, the second


volunteers who completed the first phase of the clinical trial on March 27 have ended centralized medical observation and are in good condition. The second pha

phase has remo



se will recruit 500 volunteers and introduce the placebo control group to further evaluate the immunogenicity and safety of the vaccine. As of 5 p.m. on April 13, 273 volunteers had been vaccinated. An inactivated vaccine candidate developed by the Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Si

ved the



nopharm) and the Wuhan Institute of Virology under the Chinese Academy of Sciences was approved for clinical trials on April 12, Wu said. Another inactivated vaccine candidate developed by Sinovac Research and Development Co., Ltd., a company based in

age ceil


?? the rival ??

Beijing, was approved on April 13, he added. Using killed pathogenic microorganisms to enhance the immunogenicity, inactivated vaccines have advantages of mature production process, controllable quality standards and wide protection range, according to Wang Junzhi, an a

ing to e

If you??re watching this, than don??t be a dick. Share & Like :)

Island Krk, Croatia

cademician with the Chinese Academy of Engineering. To produce the


everely ill CO
    涛嘉酒店 矿产贸易涛嘉 涛嘉食品加工?? 食品加工厂涛?? 涛嘉矿产贸易 餐饮集团涛嘉 涛嘉餐饮集团 娱乐公司涛嘉